Clozapine use in Australia

Australasian Psychiatry

Volumn 19, Issue 2, 2011, Pages 175-

  Malalagama, Geethal ^a   Bastiampillai, Tarun ^a   Dhillon, Rohan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

AUSTRALIA; CANADA; DATA BASE; DRUG COST; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; LETTER; MENTAL HEALTH SERVICE; MENTAL PATIENT; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; DATABASES, FACTUAL; DRUG MONITORING; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79953167894     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.3109/10398562.2010.525646     Document Type: Letter

References (11)

1. Royal Australian and New Zealand College of Psychiatrists. Clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39: 1-30.
2. National Institute for Healthcare and Clinical Excellence (NICE): Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal no. 43, 2002. Available from URL: http://wwwnice.org.uk. [Cited 20 November 2009].
3. Lieberman J. Comparative effectiveness of antipsychotic drugs: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study and Clinical Antipsychotic Trials of Intervention Effectiveness. Archives of General Psychiatry 2006; 63: 1069-1072. (Pubitemid 44498385)
4. Jones PB, Barnes T, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS). Archives of General Psychiatry 2006; 63: 1079-1087. (Pubitemid 44498387)
5. Tan C, Shinfuku N, Sim K. Psychotropic prescription practices in East Asia: looking back and peering ahead. Current Opinion in Psychiatry 2008; 21: 645-650.
6. Sernyak M, Rosenheck R. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services 2008; 59: 567-569.
7. Alessi-Severini S, Biscontri R, Collins D, Kozyrskyj A, Sareen J, Enns M. Utilisation and costs of antipsychotic agents: A Canadian population-based study, 1996-2006. Psychatric Services 2008l 59: 547-553.
8. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005 May; 2(5): e141. Epub 31 May 2005.
9. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD000059. DOI: 10.1002/14651858.CD000059.pub2.
10. Australian demographic statistics. Australian Bureau of statistics. 2009. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Dec%202009? OpenDocument
11. Breier A, Buchanan RW, Kirkpatrick B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 1994; 151: 20-26. (Pubitemid 24020107)